Compare W W Grainger Inc (GWW) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Mesoblast Limited — how do they compare? W W Grainger Inc trades at $1,289.79 (market cap $59.76B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: W W Grainger Inc is far larger — about 34.1× Mesoblast Limited's market cap, and W W Grainger Inc pays a 0.79% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and Mesoblast Limited for 15 Days on average.
| GWW | MESO | |
|---|---|---|
Market Cap | $59.76B | $1.75B |
Volume | 186,697 | 239,027 |
Sector | Industrials | Health |
52-Week High | $1.40K | $20.96 |
52-Week Low | $918.18 | $13.19 |
Typical Hold Time | 25 Days | 15 Days |
Enterprise Value | $61.96B | $1.83B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,289.79, up 2.08% today, with a bearish technical signal but strong fundamentals including a 47.92% ROE and recent earnings beats. The company reported Q2 2026 EPS of $12.01, beating expectations, and maintains a net income margin of 9.92%. Recent developments include the acquisition of technology assets from Adroit Worldwide Media for $210 million and the opening of a new distribution center in Oregon, supporting growth initiatives.
The outlook is mixed: analyst consensus is a hold with a $1,310 price target, but strong profitability and strategic acquisitions offer upside. Risks include high valuation multiples like a P/E of 32.34 and competitive pressures in industrial distribution. Cash flow trends improved in 2026, with net cash flow near breakeven, reducing liquidity concerns.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
